President and CEO, Pharmaceutical Research and Manufacturers of America
PhRMA’s lobbying efforts resulted in congressional Democrats watering down their drug pricing reform agenda.
Ubl leads the trade association, which represents drugmakers and biopharmaceutical research companies. He previously served as president and CEO of AdvaMed, where he facilitated reform of the Food and Drug Administration’s product review process and Medicare coverage and reimbursement of medical technologies. He also led the defense of R&D, delaying the device tax. Previously, Ubl was vice president of legislation for the Federation of American Hospitals and launched his career on Capitol Hill.
Ubl speaks: “Across the board, private insurance should work more like insurance is supposed to: spreading costs broadly and providing affordable coverage when people are sick. Insurers should also pass on more savings to patients. When insurers don’t pay full price, patients shouldn’t either.”